Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com
} Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate) } Regular clinics American Hospital General Paediatrics Skin Prick Testing Asthma / Lung function Food allergy testing/challenges } Written papers on asthma management in community in UK } Involved in study looking at why people die from asthma
} Discuss GINA guidelines of chronic management } Learning points from recent UK study Why do people die from asthma } Practical advice to help your patients } Case studies 2 nd part of lecture
Prevalence of asthma in children aged 13-14 years Global Initiative for Asthma GINA 2014 Appendix Box A1-1; figure provided by R Beasley
Asthma Diagnosis
Allergic March
Clinical Features that increase probability it is asthma?
GINA 2014 What is known about asthma? n Asthma can be effectively treated n When asthma is well-controlled, patients can ü Avoid troublesome symptoms during the day and night ü Need little or no reliever medication ü Have productive, physically active lives ü Have normal or near-normal lung function ü Avoid serious asthma flare-ups (also called exacerbations, or severe attacks)
GINA 2014 Diagnosis of asthma n The diagnosis of asthma should be based on: A history of characteristic symptom patterns Evidence of variable airflow limitation, from bronchodilator reversibility testing or other tests n Document evidence for the diagnosis in the patient s notes, preferably before starting controller treatment It is often more difficult to confirm the diagnosis after treatment has been started n Asthma is usually characterized by airway inflammation and airway hyperresponsiveness, but these are not necessary or sufficient to make the diagnosis of asthma.
GINA 2014 Typical spirometric tracings Volume Normal Flow FEV 1 Asthma (after BD) Asthma (before BD) Normal Asthma (after BD) Asthma (before BD) 1 2 3 4 5 Time (seconds) Volume Note: Each FEV 1 represents the highest of three reproducible measurements
GINA 2014 The role of lung function in asthma n n n n Diagnosis Demonstrate variable expiratory airflow limitation Reconsider diagnosis if symptoms and lung function are discordant Frequent symptoms but normal FEV 1 : cardiac disease; lack of fitness? Few symptoms but low FEV 1 : poor perception; restriction of lifestyle? Risk assessment Low FEV 1 is an independent predictor of exacerbation risk Monitoring progress Measure lung function at diagnosis, 3-6 months after starting treatment (to identify personal best), and then periodically Consider long-term PEF monitoring for patients with severe asthma or impaired perception of airflow limitation Adjusting treatment? Utility of lung function for adjusting treatment is limited by between-visit variability of FEV 1 (15% year-to-year)
Diagnosis of asthma physical examination n Physical examination in people with asthma Often normal The most frequent finding is wheezing on auscultation, especially on forced expiration n Wheezing is also found in other conditions, for example: Respiratory infections Upper airway dysfunction Endobronchial obstruction Inhaled foreign body n Wheezing may be absent during severe asthma exacerbations ( silent chest ) GINA 2014
GINA 2014, Box 2-1 Assessment of asthma 1. Asthma control - two domains Assess symptom control over the last 4 weeks Assess risk factors for poor outcomes, including low lung function 2. Treatment issues Check inhaler technique and adherence Ask about side-effects Does the patient have a written asthma action plan? What are the patient s attitudes and goals for their asthma? 3. Comorbidities Think of rhinosinusitis, GERD, obesity, obstructive sleep apnea, depression, anxiety These may contribute to symptoms and poor quality of life
GINA assessment of asthma control GINA 2014, Box 2-2A
GINA 2014, Box 2-2B Assessment of risk factors for poor asthma outcomes Risk factors for exacerbations include: Ever intubated for asthma Uncontrolled asthma symptoms Having 1 exacerbation in last 12 months Low FEV 1 (measure lung function at start of treatment, at 3-6 months to assess personal best, and periodically thereafter) Incorrect inhaler technique and/or poor adherence Smoking Obesity, pregnancy, blood eosinophilia Risk factors for fixed airflow limitation include: No ICS treatment, smoking, occupational exposure, mucus hypersecretion, blood eosinophilia Risk factors for medication side-effects include: Frequent oral steroids, high dose/potent ICS, P450 inhibitors
GINA 2014 Assessing asthma severity n How? Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations n When? Assess asthma severity after patient has been on controller treatment for several months Severity is not static it may change over months or years, or as different treatments become available n Categories of asthma severity Mild asthma: well-controlled with Steps 1 or 2 (as-needed SABA or low dose ICS) Moderate asthma: well-controlled with Step 3 (low-dose ICS/LABA) Severe asthma: requires Step 4/5 (moderate or high dose ICS/ LABA ± add-on), or remains uncontrolled despite this treatment
GINA 2014 Goals of asthma management n The long-term goals of asthma management are 1. Symptom control: to achieve good control of symptoms and maintain normal activity levels 2. Risk reduction: to minimize future risk of exacerbations, fixed airflow limitation and medication side-effects n Achieving these goals requires a partnership between patient and their health care providers Ask the patient about their own goals regarding their asthma Good communication strategies are essential Consider the health care system, medication availability, cultural and personal preferences and health literacy
Key strategies to facilitate good communication n Improve communication skills Friendly manner Allow the patient to express their goals, beliefs and concerns Empathy and reassurance Encouragement and praise Provide appropriate (personalized) information Feedback and review n Benefits include: Increased patient satisfaction Better health outcomes Reduced use of health care resources GINA 2014, Box 3-1
GINA 2014 Treating to control symptoms and minimize risk n Establish a patient-doctor partnership n Manage asthma in a continuous cycle: Assess Adjust treatment (pharmacological and non-pharmacological) Review the response n Teach and reinforce essential skills Inhaler skills Adherence Guided self-management education Written asthma action plan Self-monitoring Regular medical review
The control-based asthma management cycle GINA 2014, Box 3-2
GINA 2014, Box 3-4 (1/2) Initial controller treatment for adults, adolescents and children 6 11 years n n n n Start controller treatment early For best outcomes, initiate controller treatment as early as possible after making the diagnosis of asthma Indications for regular low-dose ICS - any of: Asthma symptoms more than twice a month Waking due to asthma more than once a month Any asthma symptoms plus any risk factors for exacerbations Consider starting at a higher step if: Troublesome asthma symptoms on most days Waking from asthma once or more a week, especially if any risk factors for exacerbations If initial asthma presentation is with an exacerbation: Give a short course of oral steroids and start regular controller treatment (e.g. high dose ICS or medium dose ICS/LABA, then step down)
GINA 2014, Box 3-4 (2/2) Initial controller treatment n Before starting initial controller treatment Record evidence for diagnosis of asthma, if possible Record symptom control and risk factors, including lung function Consider factors affecting choice of treatment for this patient Ensure that the patient can use the inhaler correctly Schedule an appointment for a follow-up visit n After starting initial controller treatment Review response after 2-3 months, or according to clinical urgency Adjust treatment (including non-pharmacological treatments) Consider stepping down when asthma has been well-controlled for 3 months
GINA 2014, Box 3-5 (upper part) Stepwise management - pharmacotherapy *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/ formoterol maintenance and reliever therapy
Stepwise management additional components GINA 2014, Box 3-5 (lower part)
} Inhaled generally preferred to oral / iv in order to provide rapid relief with fewer side effects } Systematic review shows delivery of β 2 -agonists is more effective by pmdi then nebuliser, recovery quicker, risk of admission reduced by 60%:
} More expensive } Take longer to give and more to clean } Little evidence better then spacers } Main concern is might lead to delayed presentation } Need to show family how to use spacers } GINA guidance supports spacers
} Key is use device parents want and will use } Key is use device the doctor is prepared to show the family } Pulmicort safe steroid for short term use in children and only give as neb } Encourage inh too though as child gets older
GINA 2014, Box 3-5, Step 1 Step 1 as-needed inhaled short-acting beta 2 -agonist (SABA) *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy
GINA 2014 Step 1 as-needed reliever inhaler n Preferred option: as-needed inhaled short-acting beta 2 -agonist (SABA) SABAs are highly effective for relief of asthma symptoms However. there is insufficient evidence about the safety of treating asthma with SABA alone This option should be reserved for patients with infrequent symptoms (less than twice a month) of short duration, and with no risk factors for exacerbations n Other options Consider adding regular low dose inhaled corticosteroid (ICS) for patients at risk of exacerbations
GINA 2014 SABA use a good marker of control n Definition of good control n If someone is well controlled they need 1 pmdi every 2-3 months n Ask how often need to replace inhaler n Regular use of ventolin might mean they can lead normal life, but issue of risk of exacerbation as NO EFFECT on inflammation
GINA 2014, Box 3-5, Step 2 Step 2 low-dose controller + as-needed inhaled SABA *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy
GINA 2014 Step 2 Low dose controller + as-needed SABA n n Preferred option: regular low dose ICS with as-needed inhaled SABA Low dose ICS reduces symptoms and reduces risk of exacerbations and asthma-related hospitalization and death Other options Leukotriene receptor antagonists (LTRA) with as-needed SABA Less effective than low dose ICS May be used for some patients with both asthma and allergic rhinitis, or if patient will not use ICS Combination low dose ICS/long-acting beta2-agonist (LABA) with as-needed SABA Reduces symptoms and increases lung function compared with ICS More expensive, and does not further reduce exacerbations Intermittent ICS with as-needed SABA for purely seasonal allergic asthma with no interval symptoms Start ICS immediately symptoms commence, and continue for 4 weeks after pollen season ends
GINA 2014, Box 3-5, Step 3 Step 3 one or two controllers + as-needed inhaled reliever *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy
GINA 2014 Step 3 one or two controllers + as-needed inhaled reliever n n n n Before considering step-up Check inhaler technique and adherence, confirm diagnosis Adults/adolescents: preferred options are either combination low dose ICS/ LABA maintenance with as-needed SABA, OR combination low dose ICS/ formoterol maintenance and reliever regimen* Adding LABA reduces symptoms and exacerbations and increases FEV 1, while allowing lower dose of ICS In at-risk patients, maintenance and reliever regimen significantly reduces exacerbations with similar level of symptom control and lower ICS doses compared with other regimens Children 6-11 years: preferred option is medium dose ICS with as-needed SABA Other options Adults/adolescents: Increase ICS dose or add LTRA or theophylline (less effective than ICS/LABA) Children 6-11 years add LABA (similar effect as increasing ICS) *Approved only for low dose beclometasone/formoterol and low dose budesonide/formoterol
GINA 2014, Box 3-5, Step 4 Step 4 two or more controllers + as-needed inhaled reliever *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy
GINA 2014 Step 4 two or more controllers + as-needed inhaled reliever n Before considering step-up Check inhaler technique and adherence n Adults or adolescents: preferred option is combination low dose ICS/formoterol as maintenance and reliever regimen*, OR combination medium dose ICS/LABA with as-needed SABA n Children 6 11 years: preferred option is to refer for expert advice n Other options (adults or adolescents) Trial of high dose combination ICS/LABA, but little extra benefit and increased risk of side-effects Increase dosing frequency (for budesonide-containing inhalers) Add-on LTRA or low dose theophylline *Approved only for low dose beclometasone/formoterol and low dose budesonide/formoterol
GINA 2014, Box 3-5, Step 5 Step 5 higher level care and/or add-on treatment *For children 6-11 years, theophylline is not recommended, and preferred Step 3 is medium dose ICS **For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy
GINA 2014 Step 5 higher level care and/or add-on treatment n Preferred option is referral for specialist investigation and consideration of add-on treatment If symptoms uncontrolled or exacerbations persist despite Step 4 treatment, check inhaler technique and adherence before referring Add-on omalizumab (anti-ige) is suggested for patients with moderate or severe allergic asthma that is uncontrolled on Step 4 treatment n Other add-on treatment options at Step 5 include: Sputum-guided treatment: this is available in specialized centers; reduces exacerbations and/or corticosteroid dose Add-on low dose oral corticosteroids ( 7.5mg/day prednisone equivalent): this may benefit some patients, but has significant systemic side-effects. Assess and monitor for osteoporosis See Severe Asthma Guidelines (Chung et al, ERJ 2014) for more detail
GINA 2014, Box 3-6 (2/2) Low, medium and high dose inhaled corticosteroids Children 6 11 years Inhaled corticosteroid Total daily dose (mcg) Low Medium High Beclometasone dipropionate (CFC) 100 200 >200 400 >400 Beclometasone dipropionate (HFA) 50 100 >100 200 >200 Budesonide (DPI) 100 200 >200 400 >400 Budesonide (nebules) 250 500 >500 1000 >1000 Ciclesonide (HFA) 80 >80 160 >160 Fluticasone propionate (DPI) 100 200 >200 400 >400 Fluticasone propionate (HFA) 100 200 >200 500 >500 Mometasone furoate 110 220 <440 440 Triamcinolone acetonide 400 800 >800 1200 >1200 This is not a table of equivalence, but of estimated clinical comparability Most of the clinical benefit from ICS is seen at low doses High doses are arbitrary, but for most ICS are those that, with prolonged use, are associated with increased risk of systemic side-effects
Reviewing response and adjusting treatment n n n GINA 2014 How often should asthma be reviewed? 1-3 months after treatment started, then every 3-12 months During pregnancy, every 4-6 weeks After an exacerbation, within 1 week Stepping up asthma treatment Sustained step-up, for at least 2-3 months if asthma poorly controlled Important: first check for common causes (symptoms not due to asthma, incorrect inhaler technique, poor adherence) Short-term step-up, for 1-2 weeks, e.g. with viral infection or allergen May be initiated by patient with written asthma action plan Day-to-day adjustment For patients prescribed low-dose ICS/formoterol maintenance and reliever regimen* Stepping down asthma treatment Consider step-down after good control maintained for 3 months Find each patient s minimum effective dose, that controls both symptoms and exacerbations *Approved only for low dose beclometasone/formoterol and low dose budesonide/formoterol
General principles for stepping down controller treatment n n n n n Aim To find the lowest dose that controls symptoms and exacerbations, and minimizes the risk of side-effects When to consider stepping down When symptoms have been well controlled and lung function stable for 3 months No respiratory infection, patient not travelling, not pregnant Prepare for step-down Record the level of symptom control and consider risk factors Make sure the patient has a written asthma action plan Book a follow-up visit in 1-3 months Step down through available formulations Stepping down ICS doses by 25 50% at 3 month intervals is feasible and safe for most patients See GINA 2014 report Box 3-7 for specific step-down options Stopping ICS is not recommended in adults with asthma GINA 2014, Box 3-7
GINA 2014, Box 3-8 Treating modifiable risk factors n n n n n Provide skills and support for guided asthma self-management This comprises self-monitoring of symptoms and/or PEF, a written asthma action plan and regular medical review Prescribe medications or regimen that minimize exacerbations ICS-containing controller medications reduce risk of exacerbations For patients with 1 exacerbations in previous year, consider low-dose ICS/formoterol maintenance and reliever regimen* Encourage avoidance of tobacco smoke (active or ETS) Provide smoking cessation advice and resources at every visit For patients with severe asthma Refer to a specialist center, if available, for consideration of add-on medications and/or sputum-guided treatment For patients with confirmed food allergy: Appropriate food avoidance Ensure availability of injectable epinephrine for anaphylaxis *Approved only for low dose beclometasone/formoterol and low dose budesonide/formoterol
Indications for considering referral, where available n Difficulty confirming the diagnosis of asthma Symptoms suggesting chronic infection, cardiac disease etc Diagnosis unclear even after a trial of treatment Features of both asthma and COPD, if in doubt about treatment n Suspected occupational asthma Refer for confirmatory testing, identification of sensitizing agent, advice about eliminating exposure, pharmacological treatment n Persistent uncontrolled asthma or frequent exacerbations Uncontrolled symptoms or ongoing exacerbations or low FEV 1 despite correct inhaler technique and good adherence with Step 4 Frequent asthma-related health care visits n Risk factors for asthma-related death Near-fatal exacerbation in past Anaphylaxis or confirmed food allergy with asthma GINA 2014, Box 3-10 (1/2)
Indications for considering referral, where available n Significant side-effects (or risk of side-effects) Significant systemic side-effects Need for oral corticosteroids long-term or as frequent courses n Symptoms suggesting complications or sub-types of asthma Nasal polyposis and reactions to NSAIDS (may be aspirin exacerbated respiratory disease) Chronic sputum production, fleeting shadows on CXR (may be allergic bronchopulmonary aspergillosis) n Additional reasons for referral in children 6-11 years Doubts about diagnosis, e.g. symptoms since birth Symptoms or exacerbations remain uncontrolled Suspected side-effects of treatment, e.g. growth delay Asthma with confirmed food allergy GINA 2014, Box 3-10 (2/2)
Guided asthma self-management and skills training Essential components are: n Skills training to use inhaler devices correctly n Encouraging adherence with medications, appointments n Asthma information n Guided self-management support Self-monitoring of symptoms and/or PEF Written asthma action plan Regular review by a health care provider GINA 2014
GINA 2014, Box 3-11 Provide hands-on inhaler skills training Choose Choose an appropriate device before prescribing. Consider medication options, arthritis, patient skills and cost. For ICS by pmdi, prescribe a spacer Avoid multiple different inhaler types if possible Check Check technique at every opportunity Can you show me how you use your inhaler at present? Identify errors with a device-specific checklist Correct Give a physical demonstration to show how to use the inhaler correctly Check again (up to 2-3 times) Re-check inhaler technique frequently, as errors often recur within 4-6 weeks Confirm Can you demonstrate correct technique for the inhalers you prescribe? Brief inhaler technique training improves asthma control
GINA 2014, Box 3-12 Check adherence with asthma medications n n n Poor adherence: Is very common: it is estimated that 50% of adults and children do not take controller medications as prescribed Contributes to uncontrolled asthma symptoms and risk of exacerbations and asthma-related death Contributory factors Unintentional (e.g. forgetfulness, cost, confusion) and/or Intentional (e.g. no perceived need, fear of side-effects, cultural issues, cost) How to identify patients with low adherence: Ask an empathic question, e.g. Do you find it easier to remember your medication in the morning or the evening?, or Would you say you are taking it 3 days a week, or less, or more? Check prescription date, label date and dose counter Ask patient about their beliefs and concerns about the medication
GINA 2014, Box 3-12 Inhaled corticosteroids risks n No one has ever died because they fell 1cm short of their potential final height. n Risk of drop can t be attributed to ICS alone n Children die from asthma every day n Height deficit occurs in first 2 years, and then growth velocity normalises there after n What should be our approach Careful monitoring of height and growth every review Review dose of ICS and control to see if can reduce Minimise other steroid exposure (nose and skin) Poor control, don t just increase ICS dose (see case study) Clear communication with family
GINA 2014 Strategies to improve adherence in asthma n Only a few interventions have been studied closely in asthma and found to be effective for improving adherence Shared decision-making Simplifying the medication regimen (once vs twice-daily) Comprehensive asthma education with nurse home visits Inhaler reminders for missed doses Reviewing patients detailed dispensing records
GINA 2014 Guided self-management education n Highly effective in improving asthma outcomes Reduced hospitalizations, ED visits, symptoms, night waking, time off work, improved lung function and quality of life n Three essential components Self-monitoring of symptoms and/or PEF Written asthma action plan Describe how to recognize and respond to worsening asthma Individualize the plan for the patient s health literacy and autonomy Provide advice about a change in ICS and how/when to add OCS If using PEF, base action plan on personal best rather than predicted Regular medical review
Asthma deaths 195 people who died from asthma analysed 174 expert clinical assessors 2 assessors per case who present to panel and agreement sought 28 children and young people died of asthma < 10yrs = 10 (5%) youngest 4yrs 10-19yrs = 18 (9%)
Location of death 45% of all died from asthma without any medical help during final episode 11% tried to get help but died before any help arrived 80% of < 10yrs 72% of 10-19yrs Died before reaching hospital
Personal asthma action plan } Only 23% of the 195 patients that died was there a record of them having a PAAP } Only 4/28 children had a PAAP } RECOMMENDATION All people with asthma should have PAAP that mentions: 1. Triggers and current treatment 2. How to spot symptoms getting worse and what to do then 3. What to do in emergency and when to call for help
Asthma severity * Overall data (n=155) * Mild = 14 (9%) * Moderate = 76 (49%) * Severe = 61 (39%) * In children 1. < 10 years 1. Mild 0% 2. Moderate 30% 3. Severe 60% 4. NK 10% 2. 10-19 years 1. Mild 6% 2. Moderate 44% 3. Severe 39% 4. NK 11%
Ask about control of asthma * Education is key and little evidence its being asked * Complacency of patient AND doctor * Do parents realise what should be aiming for? * Check adherence * Check ventolin use only this one helps doctor * EVERY consultation
My daughter Emily died of an asthma attack last year, she was 15. I didn t think for one second asthma would take her life. She took her medication as directed, even on day she died, but I now realise she had no asthma plan nor were we told the seriousness of her condition. I realise if we d been seen more regularly and by a specialist she d be alive now. We felt let down by our doctor
} After every admission to hospital } After 2 or more visits to ER in 1 year } If needed >2 courses of prednisolone in 1 year } Poor compliance / persistent allergy exposure